{"DataElement":{"publicId":"2180110","version":"1","preferredName":"Support Therapy Administered Type","preferredDefinition":"the agent name or a type of treatment administered to a patient to supplement protocol therapy or to aid patient recovery.","longName":"SUP_TX_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2195416","version":"1","preferredName":"Support Therapy Administered","preferredDefinition":"information related to support therapy being administered.","longName":"SUP_TX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206874","version":"1","preferredName":"Support Therapy","preferredDefinition":"Support; approval; moral, psychological, physical, or financial aid or assistance.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C37902:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Support","conceptCode":"C37902","definition":"Moral, psychological, physical, or financial aid or assistance; approval.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0C81-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED6B8282-28ED-5CC1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2180109","version":"1","preferredName":"Support Therapy Administered Type","preferredDefinition":"the agent name or a type of treatment administered to a patient to supplement protocol therapy or to aid patient recovery.","longName":"SUP_TX_ADM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Growth factors","valueDescription":"Growth factors","ValueMeaning":{"publicId":"2568061","version":"1","preferredName":"Growth factors","longName":"2568061","preferredDefinition":"Growth factors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0D326BB-3C75-5970-E034-0003BA12F5E7","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Amifostine","valueDescription":"Amifostine","ValueMeaning":{"publicId":"2568062","version":"1","preferredName":"Amifostine","longName":"2568062v1.00","preferredDefinition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amifostine","conceptCode":"C488","definition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0D326BB-3C79-5970-E034-0003BA12F5E7","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0D326BB-3C7C-5970-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Pilocarpine","valueDescription":"Pilocarpine","ValueMeaning":{"publicId":"2575475","version":"1","preferredName":"Pilocarpine","longName":"2575475","preferredDefinition":"A natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract. When applied topically to eyes, this agent stimulates the sphincter pupillae to contract, resulting in miosis; stimulates the ciliary muscle to contract, resulting in spasm of accommodation; and may cause a transitory rise in intraocular pressure followed by a more persistent fall due to opening of the trabecular meshwork and an increase in the outflow of aqueous humor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilocarpine","conceptCode":"C62068","definition":"A natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract. When applied topically to eyes, this agent stimulates the sphincter pupillae to contract, resulting in miosis; stimulates the ciliary muscle to contract, resulting in spasm of accommodation; and may cause a transitory rise in intraocular pressure followed by a more persistent fall due to opening of the trabecular meshwork and an increase in the outflow of aqueous humor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F3E0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Added current NCIt definition. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAC83853-E26D-00A3-E034-0003BA3F9857","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","deletedIndicator":"No"},{"value":"Amifostine and Pilocarpine","valueDescription":"AMIFOSTINE AND PILOCARPINE","ValueMeaning":{"publicId":"2575474","version":"1","preferredName":"AMIFOSTINE AND PILOCARPINE","longName":"2575474","preferredDefinition":"Amifostine and Pilocarpine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F3DF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAC83853-E271-00A3-E034-0003BA3F9857","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","deletedIndicator":"No"},{"value":"Deferiprone","valueDescription":"Deferiprone","ValueMeaning":{"publicId":"7135785","version":"1","preferredName":"Deferiprone","longName":"7135785","preferredDefinition":"An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferiprone","conceptCode":"C73030","definition":"An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBB8387-614B-2284-E053-F662850A9CAB","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBB8387-6164-2284-E053-F662850A9CAB","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Deferasirox","valueDescription":"Deferasirox","ValueMeaning":{"publicId":"2939024","version":"1","preferredName":"Deferasirox","longName":"2939024","preferredDefinition":"A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferasirox","conceptCode":"C48384","definition":"A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A44-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBB8387-616E-2284-E053-F662850A9CAB","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Deferoxamine","valueDescription":"Deferoxamine","ValueMeaning":{"publicId":"7135786","version":"1","preferredName":"Deferoxamine","longName":"7135786","preferredDefinition":"An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferoxamine","conceptCode":"C416","definition":"An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBB8387-6178-2284-E053-F662850A9CAB","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBB8387-6191-2284-E053-F662850A9CAB","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Thrombopoietin","valueDescription":"Thrombopoietin","ValueMeaning":{"publicId":"7135787","version":"1","preferredName":"Thrombopoietin","longName":"7135787","preferredDefinition":"A substance made by the body that helps make blood cells, especially platelets. A form of TPO made in the laboratory is called recombinant human TPO and rHu TPO. TPO is being studied as a way to increase the number of platelets in cancer patients receiving chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombopoietin","conceptCode":"C20441","definition":"Thrombopoietin (353 aa, ~38 kDa) is encoded by the human THPO gene. This protein is involved in both megakaryocyte differentiation and platelet activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBB8387-61B1-2284-E053-F662850A9CAB","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBB8387-61CA-2284-E053-F662850A9CAB","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"G-CSF","valueDescription":"G-CSF","ValueMeaning":{"publicId":"2576459","version":"1","preferredName":"G-CSF","longName":"2576459","preferredDefinition":"Colony Stimulating Factor 3, encoded by the CSF3 gene, is a cytokine that controls the production, differentiation, and function of granulocytes. The active protein is found extracellularly. Three transcript variants encoding three different protein isoforms have been found for this gene. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulocyte Colony-Stimulating Factor","conceptCode":"C26078","definition":"Granulocyte colony-stimulating factor (207 aa, ~22 kDa) is encoded by the human CSF3 gene. This protein is involved in the regulation of the production, differentiation, and function of granulocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F7B8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-07","modifiedBy":"SHIDED","dateModified":"2013-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBB8387-61EB-2284-E053-F662850A9CAB","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"Granulocyte-Macrophage Colony-Stimulating Factor","ValueMeaning":{"publicId":"5799364","version":"1","preferredName":"Granulocyte-Macrophage Colony-Stimulating Factor","longName":"5799364","preferredDefinition":"Granulocyte-macrophage colony-stimulating factor (144 aa, ~16 kDa) is encoded by the human CSF2 gene. This protein plays a role in the positive regulation of the growth and differentiation of cells in the granulocyte, macrophage, eosinophil and erythrocyte lineages.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C20545","definition":"Granulocyte-macrophage colony-stimulating factor (144 aa, ~16 kDa) is encoded by the human CSF2 gene. This protein plays a role in the positive regulation of the growth and differentiation of cells in the granulocyte, macrophage, eosinophil and erythrocyte lineages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B2F-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D256764-995C-61B1-E053-F662850A9813","beginDate":"2020-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Erythropoietin","valueDescription":"Erythropoietin","ValueMeaning":{"publicId":"2644085","version":"1","preferredName":"Erythropoietin","longName":"2644085","preferredDefinition":"Glycoprotein hormone, secreted chiefly by the kidney in the adult and the liver in the fetus, that acts on erythroid stem cells of the bone marrow to stimulate proliferation and differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythropoietin","conceptCode":"C20429","definition":"Erythropoietin (193 aa, ~21 kDa) is encoded by the human EPO gene. This protein plays a role in both erythropoiesis and the maintenance of red blood cell volume.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31378E67-E6E9-69CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-24","endDate":null,"createdBy":"GUEST","dateCreated":"2007-05-24","modifiedBy":"COLBERTM","dateModified":"2023-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D256764-9966-61B1-E053-F662850A9813","beginDate":"2020-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Thrombopoietin analog","valueDescription":"Recombinant Human Thrombopoietin","ValueMeaning":{"publicId":"7150566","version":"1","preferredName":"Recombinant Human Thrombopoietin","longName":"7150566","preferredDefinition":"A recombinantly produced form of human thrombopoietin (rHuTPO). rHuTPO stimulates platelet formation and has potential use as a therapeutic agent to prevent thrombocytopenia in patients receiving chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Human Thrombopoietin","conceptCode":"C878","definition":"A recombinantly produced form of human thrombopoietin (rHuTPO). rHuTPO stimulates platelet formation and has potential use as a therapeutic agent to prevent thrombocytopenia in patients receiving chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D256764-9939-61B1-E053-F662850A9813","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F81173C-E4A8-62B7-E053-F662850A606A","beginDate":"2020-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-02-26","modifiedBy":"ONEDATA","dateModified":"2020-02-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0D2B421-C217-5FD7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"CAMPBELB","dateModified":"2020-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811912","version":"1","longName":"Head and Neck","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000614","version":"1","longName":"Palliative Head/Neck","context":"CTEP"},{"publicId":"10000369","version":"1","longName":"Curative Head/Neck","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Type of Supportive Care Given","url":null,"context":"CTEP"},{"name":"Specify supportive treatment given","type":"Application Standard Question Text","description":"Specify supportive treatment given","url":null,"context":"NHLBI"},{"name":"Specify supportive treatment given","type":"Alternate Question Text","description":"Specify supportive treatment given","url":null,"context":"NHLBI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D0D34C8F-E26B-5974-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-13","modifiedBy":"SORENSENS","dateModified":"2020-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}